Stanford University
Showing 301-310 of 656 Results
-
Giancarlo Glick
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
BioInterested in psychedelic research, ketamine, and psychedelic-assisted therapies. I help organize Stanford Psychedelic Science Group and teach an "Introduction to Psychedelic Medicine" course at the university. Working on clinical trials of MDMA, psilocybin, and 5-meo-DMT.
-
Ira D Glick
Professor of Psychiatry and Behavioral Sciences at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsSchizophrenia is one of the major public health problems in American medicine. Treatment is partially efficacious but unsatisfactory. Accordingly, our research focuses on treatment outcome in two areas; finding more effective medications which have less side effects than current medications, and in the effects of combining medication with psychosocial interventions.
-
Gary Glover
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Psychology and of Electrical Engineering
Current Research and Scholarly InterestsMy present research is devoted to the advancement of functional magnetic resonance imaging sciences for applications in basic understanding of the brain in health and disease. We collaborate closely with departmental clinicians and with others in the school of medicine, humanities, and the engineering sciences.
-
Anna L Gloyn
Professor of Pediatrics (Endocrinology) and of Genetics
Current Research and Scholarly InterestsAnna's current research projects are focused on the translation of genetic association signals for type 2 diabetes and glycaemic traits into cellular and molecular mechanisms for beta-cell dysfunction and diabetes. Her group uses a variety of complementary approaches, including human genetics, functional genomics, physiology and islet-biology to dissect out the molecular mechanisms driving disease pathogenesis.
-
Thomas Glynn
Adjunct Lecturer, Med/Stanford Prevention Research Center
BioBiosketch - Thomas J. Glynn, M.A., M.S., Ph.D. (psych.)
Dr. Glynn is, from 2014 to the present, Adjunct Lecturer, Stanford Prevention Research Center, Stanford University School of Medicine and Executive Team Member, Mayo Clinic Global Bridges Initiative. From 1998 to 2014, he was Director, Cancer Science and Trends and Director, International Cancer Control at the American Cancer Society (ACS). In these positions, he advised the ACS about emerging research and policy issues in cancer prevention and control, recommended cancer prevention and control research and policies, and participated in the development of an international cancer control program aimed at promoting cancer prevention-related research, advocacy, treatment, and policy change, particularly in middle- and low-income nations.
Prior to the ACS, Dr. Glynn was, from 1991 to 1994, Associate Director of the U.S. National Cancer Institute's (NCI) Cancer Control Science Program and, from 1991 to 1998, Chief of the NCI's Cancer Control Extramural Research Branch. There, he directed a national program of research aimed at reducing the incidence and prevalence of cancer, primarily through dietary change, tobacco use reduction, and adherence to cancer screening guidelines. From 1983 to 1991, he was Research Director for the NCI's Smoking, Tobacco, and Cancer Program and from 1978 to 1983, he was a Research Psychologist at the National Institute on Drug Abuse.
Dr. Glynn has published widely on cancer and tobacco use prevention and control, both in the scientific literature and for consumer, professional, and patient education and is co-developer of the 4A (now 5A) protocol for the treatment of tobacco dependence. In addition to his work at the ACS and NCI, he has served as a consultant on cancer control and tobacco issues to such groups as the National Academy of Sciences/Institute of Medicine, the National Research Council, the Robert Wood Johnson Foundation, the WHO, a variety of pharmaceutical organizations, and national, state and local governments.
He has also served as a Senior Scientific Reviewer for the U.S. Surgeon General's Reports on Tobacco and Health, as Director of the World Health Organization Study of Health, Economic, and Policy Implications of Tobacco Growth and Consumption in Developing Countries, and has been active in tobacco control programs in Eastern Europe, Central America, and India. He is a Fellow of the Society for Research on Nicotine and Tobacco and his awards include the U.S. National Institutes of Health Merit Award, the Polish Ministry of Health Service Award, the Guatemala National Council for Tobacco Prevention and Control Meritorious Service Award, the Society for Research on Nicotine and Tobacco John Slade Award, and the American Society of Preventive Oncology Joseph W. Cullen Memorial Award.
